There are currently 176 active clinical trials seeking participants for Colorectal Cancer research studies. The states with the highest number of trials for Colorectal Cancer participants are California, Illinois, Ohio and New York.
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
Recruiting
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for a minimum of 3 years and up to 5 years for recurrence.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2023
Locations: Providence Facey Medical Foundation, Mission Hills, California +28 locations
Conditions: Colorectal Cancer
A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors
Recruiting
This is a study of navicixizumab monotherapy or in combination with paclitaxel or irinotecan in patients with advanced cancer. Patients will be enrolled into one of the following cancer cohorts: Cohort A: CRC Cohort B: Gastric and GEJ cancer Cohort C: TNBC Cohort D: Platinum-resistant/refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer (ovarian cancer)
Gender:
All
Ages:
18 years and above
Trial Updated:
01/30/2023
Locations: Genesis Cancer Center, Hot Springs, Arkansas +7 locations
Conditions: Colorectal Cancer, Triple Negative Breast Cancer, Gastric Cancer, Ovarian Cancer
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
Recruiting
This is a Phase II, open label, single-arm trial study of adding hydroxychloroquine to encorafenib and cetuximab in patients with metastatic BRAF V600E colon cancer with progression on at least 1 prior line of therapy. We hypothesize that autophagy is a major mechanism of resistance to BRAF inhibition in stage IV BRAF V600E colorectal cancer, and that the addition of hydroxychloroquine to standard encorafenib and cetuximab therapy will help overcome this resistance.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/16/2022
Locations: Northwestern University, Chicago, Illinois
Conditions: Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV
The Genomic Medicine at VA Study
Recruiting
This trial will determine the clinical effectiveness of polygenic risk score testing among patients at high genetic risk for at least one of six diseases (coronary artery disease, atrial fibrillation, type 2 diabetes mellitus, colorectal cancer, breast cancer, or prostate cancer), measured by time-to-diagnosis of prevalent or incident disease over 24 months.
Gender:
All
Ages:
Between 50 years and 70 years
Trial Updated:
09/29/2022
Locations: VA Boston Healthcare System, Boston, Massachusetts
Conditions: Coronary Artery Disease, Atrial Fibrillation, Type 2 Diabetes, Colorectal Cancer, Breast Cancer, Prostate Cancer
Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer
Recruiting
This research study is studying a drug in combination with radiation therapy as a possible treatment for hepatic metastases from colorectal cancer. The interventions involved in this study are: Trifluridine (TAS-102) Radiation Therapy
Gender:
All
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Colorectal Cancer
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
Recruiting
This is a Phase 1, first-in-human, open-label dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312. It is anticipated that approximately 24 subjects will be enrolled in the dose-escalation phase of the study. JAB-3312 will be administered orally once daily (QD) in 21-day treatment cycles.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2022
Locations: HealthONE Clinic Services Oncology-Hematology, Denver, Colorado +3 locations
Conditions: Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Other Solid Tumors
Longitudinal Performance of Epi proColon
Recruiting
This study will evaluate longitudinal performance of Epi proColon with respect to test positivity, longitudinal adherence to Epi proColon screening, adherence to follow-up colonoscopy and diagnostic yield, as well as assay failure rates.
Gender:
All
Ages:
Between 50 years and 74 years
Trial Updated:
10/29/2021
Locations: Veterans Affairs San Diego Healthcare System, San Diego, California +5 locations
Conditions: Colorectal Cancer, Colorectal Neoplasms
A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
Recruiting
This study is being done to answer the following question: Is the combination of the Medtronic pump and the Codman catheter device a safe alternative to the C3000 Codman pump for delivering chemotherapy directly into the liver of patients with metastatic colorectal cancer or cholangiocarcinoma?
Gender:
All
Ages:
18 years and above
Trial Updated:
12/17/2020
Locations: Virginia mason medical Center, Seattle, Washington
Conditions: Colorectal Cancer, Cholangiocarcinoma